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Background. Over the past 15 years, lactate has been used
successfully as a buffer in peritoneal dialysis solutions, although its
effectiveness in the correction of uremic acidosis and its biocom-
patibility on peritoneal resident cells have been questioned. In
addition, some investigators have suggested other potential ad-
verse metabolic effects resulting from the unphysiologically high
lactate flux into the body during CAPD. These potential problems
associated with lactate-containing CAPD solution prompted the
search for alternative buffer-containing solutions. Bicarbonate,
the physiological buffer, was considered when the problem of
calcium and magnesium carbonate solubility was solved by the use
of a two-compartment bag system, allowing the mixing of bicar-
bonate and divalent cations immediately before infusion. The
long-term tolerance, safety, efficacy and therapeutic value of a
bicarbonate-buffered peritoneal dialysis solution were evaluated
in this study.
Methods. This open, randomized, controlled, multicenter study
comparing a 34 mmol/liter bicarbonate- with a 35 mmol/liter
lactate-buffered peritoneal dialysis solution was performed in two
consecutive 12-week-treatment phases. Fourteen Centers partici-
pated in this trial.
Results. A total of 69 out of initially 123 randomized patients
completed the six-month study period (36 patients in the bicar-
bonate group and 33 in the lactate group). While the arterial acid
base status of the total study population did not change during the
study period and no significant difference was observed between
the two treatment groups, the acid-base status of patients in the
bicarbonate group entering the study with a metabolic acidosis
significantly improved (mean 6 SD; blood pH: baseline 5 7.361 6
0.05, week 12 5 7.380 6 0.04, P , 0.05; week 24 5 7.388 6 0.03
P , 0.05; plasma bicarbonate: baseline 5 19.49 6 3.01 mmol/liter,
week 12 5 21.16 6 2.63 mmol/liter, P , 0.01; week 24 5 21.51 6
2.42 mmol/liter, P , 0.01). No significant changes were recorded
in acidotic patients treated with the conventional lactate-buffered
solution. The changes in plasma bicarbonate from baseline during
the study was significantly different between the groups (week 12:
lactate 5 10.11 6 2.21 mmol/liter, bicarbonate 5 11.69 6 2.55
mmol/liter, P , 0.05, 95% confidence interval for the difference
0.21 to 2.94 mmol/liter; week 24: lactate 5 10.03 6 2.48
mmol/liter, bicarbonate 5 11.82 6 2.96 mmol/liter, P , 0.05,
95% confidence interval for the difference 0.16 to 3.42 mmol/
liter). The normalized protein catabolic rate (nPCR) slightly but
significantly decreased in the lactate group (baseline 20.90 6 0.23
g/kg/day, week 24 20.83 6 0.21 g/kg/day, P , 0.01) and increased
in the bicarbonate group (baseline 10.89 6 0.28 g/kg/day, week 24
10.92 6 0.26 g/kg/day, P , 0.05). Changes from baseline between
groups were significant (week 24, lactate 5 20.099 6 0.15
g/kg/day, bicarbonate 5 0.049 6 0.12 g/kg/day, P , 0.01, 95%
confidence interval for the difference 0.068 to 0.229 g/kg/day).
Other evaluated parameters (biochemical profile, peritoneal func-
tion parameters, dialysate protein loss) did not differ significantly
between the two groups. No adverse effects related to the study
solution were recorded.
Conclusions. These results support the efficacy and safety of
bicarbonate-buffered peritoneal solutions in a controlled random-
ized comparison for up to six months. Peritoneal dialysis solutions
containing the physiological buffer bicarbonate might effectively
replace conventional lactate-buffered CAPD solutions.
Correction of metabolic acidosis in uremic patients rep-
resents one of the fundamental aims of dialysis. In patients
with end-stage renal failure the inability of the kidney to
shed the daily metabolic acid load results in a persistent
metabolic acidosis. Part of the role of the dialysis procedure
is to provide exogenous buffer systems to neutralize this
acidosis. In continuous ambulatory peritoneal dialysis
(CAPD) the buffer is included in the fresh dialysis solution
infused daily into the peritoneal cavity.
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Bicarbonate was initially used as buffer in peritoneal
fluid by Boen in 1961 [1], but it was soon replaced by lactate
when it was found that calcium and magnesium, also
present in the solution, rapidly formed an insoluble carbon-
ate precipitate. Over the past 15 years, lactate has been
used successfully as a buffer in peritoneal dialysis solutions,
although some authors have questioned its effectiveness in
the correction of uremic acidosis [2].
In vitro studies have also demonstrated that the high
lactate concentration in combination with the low pH of the
CAPD solution might have detrimental effects on perito-
neal resident cells and their functions [reviewed in 3].
These negative effects were partially or fully restored when
bicarbonate was substituted as a buffer [reviewed in 4].
In addition, some investigators have suggested other
potentially adverse metabolic effects resulting from the
unphysiologically high lactate flux into the body during
CAPD [5].
These potential problems associated with lactate-con-
taining CAPD solution prompted the search for alternative
buffer-containing solutions. Bicarbonate, the physiological
buffer, was again considered [6] when the problem of
calcium and magnesium carbonate solubility was solved by
the use of a two compartment bag system that allowed the
mixing of bicarbonate and divalent cations immediately
before infusion [7].
A short-term pilot study in six patients treated for four
weeks with a 34 mmol/liter bicarbonate CAPD solution
demonstrated that the solution was safe and well tolerated,
did not affect dialytic adequacy, and increased serum
bicarbonate levels [8].
The present study was designated to evaluate in a larger
group of patients the long-term safety and efficacy of
bicarbonate buffered CAPD solution and to investigate the
pattern and profile of adverse reactions. Furthermore, the
overall and relative therapeutic value of this solution was
assessed in comparison with the regular lactate buffered
solution.
METHODS
Study design
This open, randomized, controlled, multicenter study
comparing a 34 mmol/liter bicarbonate- with a 35 mmol/
liter lactate-buffered peritoneal dialysis solution was per-
formed in two consecutive 12-week-treatment phases.
Fourteen Centers participated in this trial. Patients were
randomized into two groups centrally and separately for
each study center, and a so-called block randomization in
steps of four was used.
Patients were seen seven times over the 24 weeks of the
study. Visit 1 took place one week before the start of the
study, visit 2 at the beginning of the study, visit 3 after three
weeks, visit 4 after six weeks and subsequent visits occurred
at six week intervals.
This report analyses the results of those patients com-
pleting both treatment phases. The results of the first
12-week-treatment phase were reported elsewhere [9].
Patients
Patients were eligible for the study if they were aged 18
to 80 years and established on CAPD for at least three
months. All patients were free of peritonitis for at least four
weeks prior to the study. Approval was obtained from
ethical committees at each center and written informed
consent given by every patient. Patients could withdraw
from the study at any time. A temporary discontinuation
for up to four weeks was permitted in case of catheter
complications. Peritonitis per se was not a reason for
withdrawal.
Study medication
Dialysis regimen remained unchanged during the study
(3 to 5 2000 ml bag exchanges per day). Patients in both
groups used the Fresenius CAPD Safe-Lock A.N.D.Y set
system, which implies two connections during the bag
exchange. However, some patients in the lactate group
used the Fresenius CAPD Safe-Lock A.N.D.Y. Plus sys-
tem, which necessitates only one connection during the bag
exchange. The bicarbonate containing solutions were filled
in special double chamber bags with a frangible seal
between the two chambers. Patients had to break the seal
and mix the two solutions before use, the alkaline compart-
ment containing sodium bicarbonate and the acid compart-
ment containing electrolytes, glucose, and hydrochloric
acid (to adjust for pH and HCO3/CO2 equilibrium in the
final composition).
The composition of the ready-to-use solution is reported
in Table 1.
Study parameters
At each visit a physical examination was carried out that
included measurements of body wt, blood pressure and
heart rate. Blood samples for sodium, potassium, chloride,
total calcium and magnesium, ionized calcium, inorganic
phosphate, urea and creatinine were taken at each visit.
Table 1. Dialysis solution composition
Control
CAPD
2/3/4
Study
CAPD bicarbonate
20/30/40
Sodium mmol/liter 134 134
Calcium mmol/liter 1.75 1.75
Magnesium mmol/liter 0.5 0.5
Chlorine mmol/liter 103.5 104.5
L-lactate mmol/liter 35 0
Bicarbonate mmol/liter 0 34
pCO2 mm Hg — ;60
pH U 5.5 7.0–7.6
Dextrose % 1.5,2.3,4.25 1.5,2.3,4.25
Other ingredients are: water for injection, hydrochloric acid to adjust
for pH and HCO3/CO2 equilibrium.
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Arterial and venous acid base status and hematology
were evaluated at weeks 0, 6, 12, 18 and 24.
Standard biochemistry (such as, ASAT, ALAT, gGT, aP,
LDH, CPK, bilirubin, albumin, total protein, glucose, cho-
lesterol and triglycerides), and the electrocardiogram
(ECG) were evaluated at the beginning, at the middle
(week 12) and at the end (week 24) of the study period.
In addition, the residual renal function was estimated as
the average of the renal creatinine and urea clearance [10].
Furthermore, a peritoneal function test [11] was per-
formed the day prior to the clinic visit comparising a
24-hour dialysate collection including records of inflow and
drain volumes for each bag exchange, a 24-hour urine
collection, and a blood sample taken during the first
exchange at the day of the clinic visit. Dialysate samples of
each exchange were taken and both dialysate and blood
sample were analyzed for urea, creatinine, glucose and
total proteins. Urine sample were measured for volume,
urea and creatinine.
From these data, the weekly KT/V (the sum of peritoneal
and renal urea clearance multiplied by seven days and
normalized to body water), the weekly creatinine clear-
ances (the sum of peritoneal and renal creatinine clearance
multiplied by seven days and normalized to 1.73 m2 body
surface area), and the daily protein catabolic rate normal-
ized to body wt (nPCR) were calculated according to Gotch
and Keen [12]. The body surface area (BSA) was calculated
using the DuBois equation [13]. The urea distribution
volume (V) was derived from gender and BSA [14].
In addition, adverse symptoms were recorded using a
standardized questionnaire. Fourteen symptoms divided
into three categories were recorded: local effects (pain
during infusion, constipation and diarrhea), uremic effects
(itching, headache, restless legs, tiredness, loss of appetite)
and volume effects (thirst, ankle swelling, abdominal full-
ness, difficulty in maintaining correct weight, circulatory
troubles and shortness of breath). The symptoms were
graded according to their severity from 0 (no symptom) to
3 (severe, defined as a constant interference with the usual
routine). The sum of scores in each category was calcu-
lated.
Laboratory methods
Biochemical parameters were measured using standard
laboratory methods established in each Center.
Acid-base status was evaluated by measuring pH and
pCO2 using conventional blood gas analyzer. Actual bicar-
bonate concentration was calculated from the Henderson-
Hasselbalch equation.
Statistical analysis
Statistical analysis was carried out on a intention-to-treat
basis except for the acid-base status for which only a
per-protocol analysis was performed. The intention-to-
treat group comprised all patients who received one of the
test solutions at least once and had any data available in the
treatment phase. The analysis was performed only with the
existing data, so that the patient number was variable at
different time points.
All laboratory parameters except for acid-base status
were tested for significant differences between both treat-
ment groups and/or time course by multivariate analysis of
variance (MANOVA).
Acid-base parameters were firstly checked for Gaussian
distribution and then analyzed with unpaired and paired
t-tests. Two-tailed P values are reported.
Questionnaire scores were analyzed by the Wilcoxon
test. Data are reported as mean 6 SD.
RESULTS
A total of 123 patients were randomized either to the
treatment group using bicarbonate-buffered solutions (N 5
66) or to the control group using lactate-buffered solutions
(N 5 57) for 12 weeks. This 12-week-period was finished by
109 patients. The results have been published elsewhere
[9].
Seventy-three patients (37 patients in the bicarbonate
group and 36 in the lactate group) agreed to stay on the
regimen and are presented here. Before the end of the
study (24th week) two patients in the lactate group had
been transferred to hemodialysis because of severe perito-
nitis, and two patients (one in the bicarbonate and one in
the lactate group) were withdrawn for cerebral stroke.
Table 2 shows the characteristics of patients eligible for
analysis.
No differences were recorded between groups for age,
sex, weight, duration of dialysis and peritonitis rate prior to
the study. In the lactate group the most common cause of
end-stage renal failure was glomerolonephritis, while in the
Table 2. Patient characteristics
Lactate Bicarbonate
N valid patients 36 37
Females 16 20
Males 20 17
Age years
Median 55 54.5
Range 21.2–79.4 18.6–78.0
Weight (Kg)
Median 69.8 64.2
Range 46.5–98.8 49–87.5
Duration of CAPD therapy months
Median 14 15
Range 3–88 3–59
Peritonitis/patient months 1:23 1:36
Primary renal disease
Glomerulonephritis 11 5
Cystic kidney disease 4 7
Nephroangiosclerosis 6 8
Tubulointerstitial disease 2 8
Diabetes 6 5
Systemic disease 1 4
Unknown 6 0
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bicarbonate group nephroangiosclerosis and tubulointersti-
tial nephropathy prevailed.
Acid-base status
The arterial acid-base status of the whole population did
not significantly change during the study period. Figure 1
shows the arterial bicarbonate course in both groups.
This analysis does not include eight patients (4 in the
bicarbonate and 4 in the lactate group) because of protocol
violations or absence of baseline.
At the beginning of the study different acid base profiles
were recorded. Six patients (3 in lactate and 3 in bicarbon-
ate group) displayed various degrees of metabolic alkalosis
(arterial plasma bicarbonate higher than 26.1 mmol/liter).
The majority of these patients decreased their levels of
plasma bicarbonate during the study.
Eight patients (3 in lactate and 5 in bicarbonate) entered
the study with a normal acid base status (arterial plasma
bicarbonate from 23.5 to 26.1 mmol/liter). During the study
the arterial bicarbonate of the majority of these patients
fluctuated within the normal range.
The remaining 26 lactate patients and 25 bicarbonate
patients started the study with various degree of metabolic
acidosis. Table 3 shows the plasma pH, pCO2 and bicar-
bonate values of these patients during the study. No
differences were recorded in the lactate group at any time
periods and parameters. Arterial pH and bicarbonate sig-
nificantly increased in the bicarbonate group at weeks 12
and 24.
Figure 2 shows the plasma bicarbonate concentration
differences from baseline in both groups of patients with
metabolic acidosis at baseline. The differences between
groups were statistically significant at weeks 12 and 24.
Dialysis dose and adequacy
Body weight did not change significantly during the
24-week observation period in both groups (lactate group,
68.2 6 13.3 kg at baseline and 68.8 6 12.0 kg at 24 weeks;
bicarbonate group, 64.4 6 12.0 kg at baseline and 65.2 6
9.1 kg).
Residual renal function decreased in both groups with-
out statistically significant difference between groups. In
the lactate group, renal creatinine clearance decreased
from 3.6 6 4.1 (median 2.3) ml/min at baseline to 3.0 6 3.3
(median 2.1) ml/min after 24 weeks. In the bicarbonate
group, renal creatinine clearance was 2.7 6 2.8 (median
1.9) ml/min at baseline and 2.8 6 4.4 (median 1.7) ml/min
at week 24.
No statistical differences were recorded between the
groups for the following parameters: KT/V peritoneal and
KT/V total (peritoneal 1 renal), weekly creatinine clear-
ance peritoneal and total (peritoneal 1 renal), D/P urea,
daily net ultrafiltration (UF), normalized UF (expressed as
milliliters of daily ultrafiltration/g of glucose daily applied)
and daily dialysate protein loss.
The normalized protein catabolic rate (nPCR) signifi-
cantly decreased during the study in the lactate group
(0.90 6 0.23 g/kg/day at baseline to 0.85 6 0.23 g/kg/day at
week 24, P , 0.01) and significantly increased in the
bicarbonate group (0.89 6 0.28 g/kg/day at baseline to
0.93 6 0.25 g/kg/day at week 24, P , 0.05).
Figure 3 shows the nPCR differences from baseline in
lactate and bicarbonate groups. The differences between
groups were statistically significant at week 24.
During the 24-week observation period the biochemical
profile did not significantly change either within nor be-
tween the treatment groups. A summary is presented in
Table 4.
Subjective assessment
The average scores of the three symptom categories are
reported in Table 5.
The sum of symptom scores joined into “local effects”
(pain during the fluid infusion, constipation and diarrhea)
statistically decreased during treatment with bicarbonate
solution, while it remained unchanged in the control group.
No difference between groups were recorded at any time.
Adverse events
Adverse events during the study are reported in Table 6.
None of the adverse events seemed to be related to the type
of buffer.
The peritonitis rate during the study was higher in the
bicarbonate group, but there was not significant difference
between the two groups. It should be noted that during the
study bicarbonate patients used a double connection sys-
tem, while in several centers lactate patients used a single
connection system. In addition, more patients in bicarbon-
ate group entered the study with an exit site infection and,
in the same group, some patients developed an exit site
infection during the study.
Fig. 1. Time course of arterial plasma bicarbonate concentration during
the study (f lactate, N 5 32;  bicarbonate, N 5 33).
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DISCUSSION
This study, completed by 69 patients, is the first long-
term randomized controlled study to our knowledge that
was performed to compare the efficacy and safety of the
physiological buffer, bicarbonate, with conventional lactate
buffered CAPD solutions.
In the last decade many studies have dealt with various
aspects of peritoneal dialysis fluid biocompatibility. There
is a firm in vitro evidence that commercial CAPD solutions
affect the viability and function of mesothelial cells and
peritoneal leukocytes [3]. These detrimental effects have
been attributed to several factors, including the low pH of
the solution in combination with a high lactate concentra-
tion. In vitro studies have demonstrated that a bicarbonate
solution with a neutral pH may totally or partially reverse
these undesired effects [4].
The systemic effects of an exogenous lactate load are
well known. These include a lowering of the cellular redox
state ([NAD1]/[NADH] ratio) and the linked phosphory-
lation potential ([ATP]/[ADP][Pi] ratio), thus impairing
many vital cellular functions [15]. In addition, it induces a
catabolic state potentiating the conversion of muscle pro-
tein into glucose [16]. Although the lactate load in CAPD
results in an additional 20% to 30% of the normal daily
metabolic production [17], the clinical relevance of this
increase has not yet been demonstrated.
Bicarbonate, the physiological buffer, is, however, an
obvious choice for buffering the peritoneal dialysis fluid. It
use in the past has been prevented by the precipitation of
insoluble calcium and magnesium carbonate during steam
sterilization. When this problem was solved by the use of a
double chamber bag allowing the mixing of bicarbonate
and divalent cations only just before the use [6], a bicar-
bonate buffered solution, suitable for clinical use, became
available for a pilot study [8].
In this long-term study involving a large number of
patients, the use of the bicarbonate buffered solution was
not associated with any adverse event. Subjective patient
well-being was improved mainly because of a reduction in
abdominal pain induced by the standard lactate solution.
This effect of the bicarbonate solution was already demon-
strated in some anecdotal studies [18].
At baseline evaluation a wide range of patient’s acid-base
status was recorded: 9.23% of patients were alkalotic, 12.3%
had a normal acid-base status and 78.46% were acidotic.
During the study, and despite the fact that the acid-base
status of the two groups of patients did not significantly
change as a whole, plasma bicarbonate concentrations of
Fig. 2. Arterial plasma bicarbonate concentration differences from base-
line. Symbols are: lactate, dotted line; bicarbonate, solid line. During week
12, lactate 5 0.11 6 2.21 mmol/liter, bicarbonate 1.69 6 2.55 mmol/liter
P , 0.05, 95% confidence interval for the difference 0.21 to 2.94
mmol/liter (lactate, N 5 26; bicarbonate, N 5 25). During week 24,
lactate 5 0.03 6 2.48 mmol/liter, bicarbonate 1.82 6 2.96 mmol/liter, P ,
0.05, 95% confidence interval for the difference 0.16 to 3.42 mmol/liter
(lactate N 5 23, bicarbonate N 5 24).
Fig. 3. Daily protein catabolic rate normalized to body weight (nPCR)
differences from baseline. Symbols are: lactate, dotted line; bicarbonate,
solid line. At week 24 lactate 5 20.099 6 0.15 g/kg/day, bicarbonate 5
0.049 6 0.12 g/kg/day, P , 0.01, 95% confidence interval for the difference
0.068 to 0.229 g/kg/day (lactate, N 5 33; bicarbonate, N 5 36).
Table 3. Arterial acid-base parameters in patients with metabolic acidosis
Baseline Week 6 Week 12 Week 18 Week 24
pH U
Lac 7.370 6 0.03 7.379 6 0.04 7.381 6 0.04 7.361 6 0.06 7.380 6 0.04
Bic 7.361 6 0.05 7.383 6 0.05a 7.380 6 0.04a 7.356 6 0.08 7.388 6 0.03a
pCO2 mm Hg
Lac 37.18 6 3.81 36.89 6 4.00 36.47 6 3.58 36.32 6 4.20 36.93 6 5.10
Bic 35.05 6 5.07 34.60 6 4.80 36.48 6 3.60 36.79 6 4.10 36.58 6 4.46
HCO3 mmol/liter
Lac 21.01 6 1.94 21.34 6 2.62 21.12 6 2.13 20.04 6 4.25 21.51 6 2.42
Bic 19.46 6 3.01 20.18 6 2.88 21.16 6 2.63b 21.04 6 3.19 21.51 6 2.42b
a P , 0.05 from baseline; b P , 0.01 from baseline
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acidotic patients in bicarbonate group increased of about 2
mmol/liter and tended to decrease in patients with alkalo-
sis. On the contrary, in the lactate group, no substantial
changes of distribution values were recorded. The small
fraction of patient with metabolic alkalosis or normal
acid-base status did not allow a statistical evaluation.
Theoretically, equal amounts of buffers in the fresh
dialysis solution should provide equal degrees of acidosis
correction irrespective of the kind of buffer used. A possi-
ble explanation for this beneficial effect of the bicarbonate
buffered solutions is that different CAPD buffers achieve
the dialytic base gain by different mechanisms. During
CAPD exchanges with the lactate buffered solution, a
remarkable amount of endogenous bicarbonate is lost
across the peritoneal membrane. Consequently, to normal-
ize body base balance, the lactate flux from the dialysis
solution to the patient should restore not only the bicar-
bonate consumed in the metabolic processes but also
counterbalance these endogenous losses. The latter repre-
sent about 75% of the total lactate flux. This mechanism is
clearly not convenient from a kinetic point of view, since
large buffer fluxes are required to achieve small changes in
plasma bicarbonate [19].
Since no endogenous bicarbonate is lost into dialysate
using a bicarbonate buffered peritoneal dialysis solution,
only few millimoles of dialytic bicarbonate are gained per
exchange and they are effective in balancing the daily
metabolic acid production.
This mechanism could be also beneficial for the small
percentage of patients with metabolic alkalosis. Unfortu-
nately, the very low number of patients with this acid-base
derangement at the baseline did not allow us to draw any
conclusion in this study.
Table 4. Biochemical profile during the study (mean 6 SD)
Baseline Week 6 Week 12 Week 18 Week 24
Sodium mmol/liter
Lac 140 6 4.1 141 6 4.1 140 6 3.7 140 6 3.6 141 6 3.3
Bic 140 6 3.8 139 6 3.2 140 6 3.7 140 6 4.6 139 6 3.9
Potassium mmol/liter
Lac 4.3 6 0.96 4.5 6 0.83 4.4 6 0.88 4.5 6 0.93 4.4 6 0.91
Bic 4.4 6 0.89 4.5 6 0.87 4.3 6 0.85 4.4 6 0.85 4.6 6 0.82
Ionized calcium mmol/liter
Lac 1.26 6 0.13 1.25 6 0.12 1.24 6 0.15 1.26 6 0.14 1.29 6 0.12
Bic 1.21 6 0.13 1.21 6 0.08 1.19 6 0.15 1.23 6 0.11 1.24 6 0.12
Phosphate mmol/liter
Lac 1.60 6 0.45 1.55 6 0.45 1.68 6 0.48 1.61 6 0.57 1.66 6 0.50
Bic 1.61 6 0.48 1.63 6 0.46 1.62 6 0.43 1.63 6 0.45 1.65 6 0.48
BUN mg/dl
Lac 62.7 6 19.4 61.5 6 18.8 61.4 6 19.4 62.1 6 18.1 61.5 6 17.4
Bic 60.4 6 22.9 61.4 6 21.5 60.8 6 21.0 63.5 6 20.0 64.6 6 20.9
Creatinine mg/dl
Lac 9.85 6 2.90 9.87 6 2.90 9.96 6 2.70 9.99 6 2.83 9.80 6 2.72
Bic 9.56 6 2.72 9.83 6 2.87 9.75 6 2.95 9.75 6 2.67 9.95 6 3.16
Hemoglobin g/dl
Lac 11.0 6 1.7 10.9 6 2.0 10.9 6 2.0 10.8 6 2.1 11.1 6 1.6
Bic 10.9 6 2.1 11.1 6 2.1 11.3 6 2.2 11.2 6 2.4 11.0 6 2.1
Albumin g/dl
Lac 3.73 6 0.50 3.66 6 0.47 3.79 6 0.41
Bic 3.82 6 0.41 3.63 6 0.46 3.66 6 0.47
Table 5. Scores of symptom questionnaire
Baseline Week 12 Week 24
Local effects
Lac 0.36 6 0.70 0.55 6 1.00 0.45 6 0.87
Bic 0.72 6 1.11 0.22 6 0.54a 0.25 6 0.60b
Uremic effects
Lac 1.39 6 1.62 1.52 6 2.02 1.34 6 1.45
Bic 0.86 6 1.07 0.78 6 1.15 0.92 6 1.54
Volume effects
Lac 1.67 6 1.31 1.91 6 2.01 2.33 6 2.22
Bic 2.00 6 1.99 1.58 6 1.59 1.69 6 1.77
a P , 0.05 from baseline; b P , 0.01 from baseline
Table 6. Adverse events
Lactate Bicarbonate
Myocardial angina 1
Arthritis 1
Hypervolemia 2
Enteritis 2
Hernia 1
Hyperglycemia 1
Hypertension (de novo) 1
Hypotension 1
Apoplexy 1 1
Pancreatitis 1
Vomiting 1
Hypercalcemia 1
Exit site infection at baseline
during the study
1 3
3
Peritonitis 10 12
Peritonitis/patient months 20 17
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A significant increase in normalized protein catabolic
rate was recorded in the bicarbonate group. In addition,
BUN slightly, but not statistically, increased even though
no changes in urea nitrogen clearance were registered. This
effect is generally attributed to an increase of dietary
protein intake. However, no attempt was made to assess the
daily protein intake. Therefore, it cannot be concluded that
nutrition improved in bicarbonate group even if our data
suggests this effect.
The present results could appear to be in conflict with
studies in which the influence of metabolic acidosis correc-
tion on protein metabolism were investigated. It has been
shown that the short-term correction of metabolic acidosis
in predialysis [20] and in hemodialysis patients [21] has a
beneficial effect on protein metabolism with a fall of BUN
levels.
These data were confirmed in peritoneal dialysis [22]. In
eleven peritoneal dialysis patients treated for two weeks
with a sodium bicarbonate oral supplementation, the ex-
pected increase in plasma bicarbonate concentration was
associated with a decrease in BUN and nPCR. Since
dietary protein intake was kept constant, an anabolic effect
of acidosis correction was suggested. In our study dietary
protein intake was not controlled and the extent of plasma
bicarbonate increase was lower than that observed in the
study of Stein et al (2 vs. 4 mmol/liter) [22].
The therapeutic value of the bicarbonate solution was
equal to that of conventional lactate buffered solution.
Experimental investigations in a rat model have shown a
more favorable ultrafiltration profile of a neutralized peri-
toneal dialysis solution as compared with a conventional
acidic solution [23, 24]. This effect was attributed to the less
initial peritoneal membrane irritation and vasodilation. In
this multicenter study net ultrafiltration did not change
using the bicarbonate neutral solution. However, recent
computer simulations [25] have predicted that the differ-
ence in ultrafiltrated volume between acidic and neutral
solutions at four hours dwell would theoretically be of
around 100 milliliters. Since the intra-patient and inter-
patient variations in drained volume is normally very large,
the increase of net ultrafiltration of this magnitude is
difficult to detect clinically even in a relative large number
of patients.
This large multicenter, randomized, controlled study has
demonstrated that a 34 mmol/liter bicarbonate buffered
CAPD solution was well tolerated over six months, did not
alter peritoneal dialysis adequacy and was more effective
than conventional 35 mmol/liter lactate buffered solution in
acidosis correction. However, in order to achieve a full,
ultimate correction of acid-base status also of the heavier
CAPD population, a second formulation with a higher
bicarbonate content in the CAPD solution might be re-
quired.
In addition, the safety aspect of this study demonstrated
that a bicarbonate solution is suitable for the CAPD
population. Therefore, as bicarbonate is the physiological
buffer of the body and the bicarbonate peritoneal dialysis
solution is more biocompatible than the conventional so-
lution, it should become the solution of choice.
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